JIC
BXRX

Johnson Investment Counsel’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Johnson Investment Counsel’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-7
Closed -$28K – 615
2020
Q3 		$28K Hold
7
– – ﹤0.01% 572
2020
Q2 		$42K Buy
+7
New +$33.6K ﹤0.01% 575

Other funds holding BXRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Johnson Investment Counsel's BXRX Position: Q4 2020 in Review

Johnson Investment Counsel sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q4 2020, closing a stake of 7 shares — an estimated $28K sold.

Johnson Investment Counsel first reported a position in BXRX in Q2 2020 and held it in 2 quarters. The position peaked at $42K in Q2 2020. 34 funds tracked by Wall St. Rank hold BXRX as of Q4 2020.

  • Johnson Investment Counsel reported no remaining Baudax Bio, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Johnson Investment Counsel sold 7 Baudax Bio, Inc. Common Stock shares in Q4 2020, an estimated $28K.
  • Johnson Investment Counsel first reported a position in Baudax Bio, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • Johnson Investment Counsel's Baudax Bio, Inc. Common Stock position peaked at $42K in Q2 2020.
  • 34 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q4 2020.

Based on Johnson Investment Counsel's 13F filing for Q4 2020, filed 12 Feb 2021.